These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31697454)

  • 1. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2.
    Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Lane W; Sang BC; Saikatendu K; Matsunaga S; Miwatashi S
    ChemMedChem; 2019 Dec; 14(24):2093-2101. PubMed ID: 31697454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
    Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Snell G; Bertsch R; Nguyen J; Sang BC; Miwatashi S
    ChemMedChem; 2019 May; 14(10):1022-1030. PubMed ID: 30945818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
    Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
    Koch P; Jahns H; Schattel V; Goettert M; Laufer S
    J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
    Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
    Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
    Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
    J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
    Bamford MJ; Bailey N; Davies S; Dean DK; Francis L; Panchal TA; Parr CA; Sehmi S; Steadman JG; Takle AK; Townsend JT; Wilson DM
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3407-11. PubMed ID: 15955699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
    Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
    J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors.
    Heider F; Haun U; Döring E; Kudolo M; Sessler C; Albrecht W; Laufer S; Koch P
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29036906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.
    Koch DA; Silva RB; de Souza AH; Leite CE; Nicoletti NF; Campos MM; Laufer S; Morrone FB
    Rheumatology (Oxford); 2014 Mar; 53(3):425-32. PubMed ID: 24241037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
    Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
    J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
    Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
    J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
    Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
    J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridinylimidazole based p38 MAP kinase inhibitors.
    Jackson PF; Bullington JL
    Curr Top Med Chem; 2002 Sep; 2(9):1011-20. PubMed ID: 12171568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors.
    Bamford MJ; Alberti MJ; Bailey N; Davies S; Dean DK; Gaiba A; Garland S; Harling JD; Jung DK; Panchal TA; Parr CA; Steadman JG; Takle AK; Townsend JT; Wilson DM; Witherington J
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3402-6. PubMed ID: 15950465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.